MONTREAL and CHARLOTTE, N.C., Oct. 24, 2023 /CNW/ -- Milestone® Pharmaceuticals Inc. (Nasdaq:MIST) today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for etripamil for the treatment of paroxysmal supraventricular tachycardia (PSVT). PVST is a condition characterized by an abnormality in the electrical system of the heart causing patients to have unexpected, often severely symptomatic episodes of rapid heart rate.
Read more at newswire.caMilestone Pharmaceuticals Announces Submission of New Drug Application to the U.S. FDA for Etripamil
Newswire.ca -
Tue Oct 24, 2023
Columnist
Contributor Content
Press Release
Sponsored Content
All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here
This article could contain syndicated content. We have not reviewed, approved, or endorsed the content and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here
All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here
/Palantir%20(PLTR)%20by%20Piotr%20Swat%20via%20Shutterstock.jpg)
/Micron%20Technology%20Inc_%20logo%20on%20building-by%20vzphotos%20vis%20iStock.jpg)
/A%20concept%20image%20of%20a%20self-driving%20car%20image%20by%20Gorodenkoff%20via%20Shutterstock.jpg)